Labcorp Holdings Inc. (LH) key performance indicators and operating metrics (10 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Revenue (total) | 3.54B | FY2026-Q1 |
| Adjusted earnings per share | 4.25 USD_per_share | FY2026-Q1 |
| Backlog (BLS) | 8.64B | FY2026-Q1 |
| Free cash flow (Free Cash Flow) | 70.5M | FY2026-Q1 |
| TTM Book to Bill | 1.04 ratio | FY2026-Q1 |
| TTM Net Orders | 3.29B | FY2026-Q1 |
| Biopharma Laboratory Services revenue (total) | 793M | FY2025-Q4 |
| Diagnostics Laboratories revenue (total) | 2.73B | FY2025-Q4 |
| Adjusted Operating Income - Biopharma Laboratory Services Segment (AOI) | 132.2M | FY2025-Q3 |
| Adjusted Operating Income - Diagnostics Laboratories Segment (AOI) | 450.4M | FY2025-Q3 |
Back to LH overview · LH earnings · LH holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.